CAMP (Camp4 Therapeutics) Capex-to-Revenue: 0.00 (As of Mar. 2026)


CAMP Camp4 Therapeutics Corp CAMP
6 GF Score
Price $4.20
! 3 Warning Signs
View Full Analysis

What is Camp4 Therapeutics Capex-to-Revenue?

Camp4 Therapeutics CAMP -3.00% 6 Capex-to-Revenue is 0.00 as of Mar. 2026. GuruFocus rates CAMP with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Camp4 Therapeutics's Capital Expenditure for the three months ended in Mar. 2026 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2026 was $1.29 Mil.

Hence, Camp4 Therapeutics's Capex-to-Revenue for the three months ended in Mar. 2026 was 0.00.

Camp4 Therapeutics  (NAS:CAMP) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Camp4 Therapeutics Capex-to-Revenue Related Terms

Camp4 Therapeutics Capex-to-Revenue Historical Data

* Premium members only.

The historical data trend for Camp4 Therapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camp4 Therapeutics Capex-to-Revenue Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Capex-to-Revenue
0.00 1.94 0.68 0.08

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.00 0.00 0.00 0.00

CAMP vs NERV, YDES, IKT: Capex-to-Revenue Comparison

For the Biotechnology subindustry, Camp4 Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Camp4 Therapeutics Capex-to-Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's Capex-to-Revenue falls into.


CAMP
6GF Score
Camp4 Therapeutics Corp CAMP
Capex-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camp4 Therapeutics Capex-to-Revenue Calculation

Camp4 Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.279) / 3.498
=0.08

Camp4 Therapeutics's Capex-to-Revenue for the quarter that ended in Mar. 2026 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 1.294
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Capex-to-Revenue →
What does a Capex-to-Revenue of 0.00 mean?
Camp4 Therapeutics (CAMP) has a Capex-to-Revenue of 0.00 as of Mar. 2026. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Camp4 Therapeutics and its competitors.
Is Camp4 Therapeutics' Capex-to-Revenue too high?
Camp4 Therapeutics' current Capex-to-Revenue is 0.00. Overall, Camp4 Therapeutics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Camp4 Therapeutics' Capex-to-Revenue compare to NERV and YDES?
Camp4 Therapeutics' Capex-to-Revenue of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Revenue for a Biotechnology company?
A good Capex-to-Revenue depends on the Biotechnology industry context. However, Capex-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Revenue mean?
A high Capex-to-Revenue can signal that a stock is expensive relative to its fundamentals. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Camp4 Therapeutics and its competitors. Camp4 Therapeutics's current Capex-to-Revenue is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camp4 Therapeutics stock overvalued right now?
Camp4 Therapeutics (CAMP) has a current Capex-to-Revenue of 0.00. The current Capex-to-Revenue is 0.00. Camp4 Therapeutics' overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Revenue calculated?
Capex-to-Revenue is calculated from a company's financial statements. For Camp4 Therapeutics (CAMP), the current Capex-to-Revenue is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Camp4 Therapeutics Business Description

Address One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA, 02139
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
6GF Score

Get the complete analysis for CAMP

Capex-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.20
Price